The DOI matches its Crossref record.
Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension
Abstract
OBJECTIVE: To examine the efficacy and tolerability of the neutral endopeptidase inhibitor, candoxatril (UK 79,300) as monotherapy in essential hypertension. DESIGN: Double-blind, placebo-controlled, parallel-group study of 28 days' duration. SETTING: Three hospital outpatient departments participating in the Glasgow Blood Pressure Clinic (Glasgow, UK). PATIENTS: Forty patients with essential hypertension with diastolic blood pressure 95-114 mmHg after a 2-4 week placebo run-in period. INTERVENTIONS: Twenty-eight days' treatment with candoxatril 200 mg twice daily or matching placebo capsules. MAIN OUTCOME MEASURES: Changes in supine and erect blood pressure, and volunteered side effects during double-blind treatment. RESULTS: When measured at the end of the dose interval, the fall in supine blood pressure following candoxatril was not significantly greater than that after placebo. Compared with placebo, a significant effect for candoxatril was seen only for systolic blood pressure in the erect posture; the fall in erect diastolic blood pressure attributable to candoxatril was insignificant. Median plasma atrial natriuretic peptide concentration increased in candoxatril-treated patients and decreased in the placebo group. No stimulation of the renin-aldosterone axis was seen. There was a non-significant trend towards greater urinary excretion of cyclic guanosine monophosphate after candoxatril. Mean plasma concentration of candoxatril at (UK 73,967--the active metabolite of candoxatril) reached a peak of 1010 +/- 437 ng/ml after acute dosing, and 1328 +/- 405 ng/ml after chronic dosing; time to maximum concentration was 2 h in each case. Candoxatril was well-tolerated; numbers of adverse events did not differ between active treatment and placebo. CONCLUSIONS: Although atrial natriuretic peptide levels were significantly increased, candoxatril 200 mg twice daily for 28 days did not produce a clinically relevant fall in blood pressure. Our results cast some doubt upon the role of neutral endopeptidase inhibition in the treatment of unselected hypertensive patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ruilope, L. M., Dukat, A., Böhm, M., Lacourcière, Y., Gong, J., & Lefkowitz, M. P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61966-8 · Cited by 599
Endothelin as a regulator of cardiovascular function in health and disease
Haynes, W. G., & Webb, D. J. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816080-00001 · Cited by 360
Volpe, M., Carnovali, M., & Mastromarino, V. (2015) · Clinical Science · doi:10.1042/cs20150469 · Cited by 305
von Lueder, T. G., Wang, B. H., Kompa, A. R., Huang, L., Webb, R., Jordaan, P., Atar, D., & Krum, H. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001785 · Cited by 290
Natriuretic peptides in cardiovascular diseases: current use and perspectives
Volpe, M., Rubattu, S., & Burnett, J. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht466 · Cited by 277
Metadata
- Authors
- Bevan, E. G., Connell, J. M. C., Doyle, J., Carmichael, H. A., Davies, D. L., Lorimer, A. R., & Mclnnes, G. T.
- Venue
- Journal of Hypertension
- Published
- 1992-07
- Volume
- 10
- Issue
- 7
- Pages
- 607???614
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2126871516
- Cited by
- 175
- References
- 0
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. https://app.cochat.ai/papers/10.1097/00004872-199207000-00002
- The paper
- Bevan, E. G., Connell, J. M. C., Doyle, J., Carmichael, H. A., Davies, D. L., Lorimer, A. R., & Mclnnes, G. T. (1992). Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. Journal of Hypertension. https://doi.org/10.1097/00004872-199207000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.